Pharmacotherapy for obesity: moving towards efficacy improvement.

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsWalmir Coutinho is a speaker for Novo Nordisk, Brace Pharma and Takeda and an advisory board member of Merck, Novo Nordisk, Abbott Diabetes Care, Takeda and EMS. Bruno Halpern is an advisory board member of Merck, Novo Nordisk, Lilly, and Astra Zeneca and has received funding for lectures from Novo Nordisk, Lilly, Astra Zeneca Boehringer Ingelheim, Takeda, and Abbott Nutrition. Competing interests Walmir Coutinho is a speaker for Novo Nordisk, Brace Pharma and Takeda and an advisory board member of Merck, Novo Nordisk, Abbott Diabetes Care, Takeda and EMS. Bruno Halpern is an advisory board member of Merck, Novo Nordisk, Lilly, and Astra Zeneca and has received funding for lectures from Novo Nordisk, Lilly, Astra Zeneca Boehringer Ingelheim, Takeda, and Abbott Nutrition."

"Funding Novo Nordisk Farmacêutica do Brasil LTDA provided financial support for assistance from a medical writer but played no role in the content of this publication."